Vaping and E-Cigarettes in Respiratory Care

Vaping and e-cigarette use have become important topics in respiratory care because they involve inhaled substances that can affect the lungs, airways, and overall health. Although many people view vaping as safer than cigarette smoking, respiratory therapists should not treat it as harmless.

Vaping is associated with nicotine addiction, youth tobacco exposure, chemical inhalation, possible lung injury, and progression to cigarette use.

For this reason, vaping should be included in patient assessment, documentation, education, prevention efforts, and tobacco cessation counseling.

 

What Is Vaping?

Vaping refers to the use of an electronic device to heat a liquid and create an aerosol that is inhaled into the lungs. These devices are often called e-cigarettes, vape pens, pod systems, electronic nicotine delivery systems, or vaping devices. Some people also use the term “juuling” when referring to a specific brand or style of pod-based device.

The liquid used in these devices may contain nicotine, flavoring chemicals, vegetable glycerin, propylene glycol, tetrahydrocannabinol, cannabidiol, or other substances. The device heats the liquid so the user can inhale the aerosol. Although the aerosol is sometimes called vapor, it is not simply harmless water vapor. It may contain nicotine, ultrafine particles, heavy metals, volatile organic compounds, carcinogens, and other chemicals that can affect lung health.

Vaping devices vary widely. Some resemble pens, USB drives, or small electronic devices, making them easy to conceal. Others are larger refillable systems that can produce more aerosol. Because the products differ in design, contents, voltage, temperature, and user behavior, the health effects may vary from one person to another.

Why Vaping Matters in Respiratory Care

Respiratory therapists care for patients with asthma, COPD, pneumonia, acute respiratory distress syndrome, lung cancer, respiratory failure, and many other pulmonary conditions. Since vaping involves inhaling chemicals directly into the respiratory tract, it is clinically relevant.

Vaping can contribute to several concerns. It may irritate the airways, worsen respiratory symptoms, expose users to harmful chemicals, increase nicotine dependence, and place young people at risk for future cigarette use. In some cases, vaping has been associated with serious lung injury requiring hospitalization, intensive care, or mechanical ventilation.

For respiratory therapists, the main point is simple: vaping history matters. It should be assessed in the same general way as cigarette smoking, occupational exposure, environmental exposure, and other inhaled risks. A patient who vapes may not consider themselves a smoker, so the therapist should ask specifically about vaping and e-cigarette use rather than only asking, “Do you smoke?”

Vaping as Part of the Patient History

A complete respiratory assessment should include the patient’s history of inhaled exposures. This includes cigarette smoking, secondhand smoke exposure, occupational dust or chemical exposure, environmental irritants, marijuana use, and vaping.

A vaping history should include more than a yes-or-no answer. Respiratory therapists may need to ask about the type of device, frequency of use, duration of use, nicotine concentration, substances vaped, flavorings used, and whether the patient uses commercially purchased or homemade products. The therapist should also ask whether the patient vapes nicotine, THC, CBD, or other substances.

Symptoms associated with vaping should also be documented. These may include cough, wheezing, shortness of breath, chest tightness, chest pain, fever, fatigue, nausea, vomiting, diarrhea, dizziness, or worsening exercise tolerance. If a patient presents with acute respiratory symptoms, recent vaping history may provide an important clue.

This is especially important because patients may not volunteer this information. Some may think vaping is unrelated to their symptoms. Others may be embarrassed or worried about disclosing nicotine, marijuana, or THC use. A nonjudgmental approach helps improve accuracy.

Vaping and Tobacco-Related Disease Risk

Traditional cigarette smoking remains one of the most important risk factors for lung cancer and chronic respiratory disease. However, e-cigarettes and vaping devices have changed the landscape of tobacco and nicotine exposure. Many people use these products instead of cigarettes, along with cigarettes, or before beginning cigarette smoking.

E-cigarettes are often discussed as newer tobacco-delivery or nicotine-delivery products. They are not the same as combustible cigarettes, but they are still relevant to respiratory disease prevention because they can deliver nicotine and other inhaled chemicals to the lungs.

One clinical concern is dual use. Many tobacco users do not use only one product. Some continue smoking cigarettes while also vaping. This may allow nicotine addiction to continue while the person remains exposed to the harmful effects of cigarette smoke. For respiratory therapists, this means tobacco assessment should include all products, not only cigarettes.

A patient may report that they “quit smoking” but still use e-cigarettes daily. This distinction matters. While stopping combustible cigarettes may reduce exposure to some toxic smoke products, ongoing vaping can still involve nicotine addiction and inhaled chemical exposure. Respiratory therapists should clarify what the patient means by quitting and should document current e-cigarette use.

Vaping and Lung Cancer Prevention

Lung cancer prevention has traditionally focused on cigarette smoking cessation, avoidance of secondhand smoke, and reduction of harmful exposures. Vaping adds another layer to prevention efforts because it may introduce young people and nonsmokers to nicotine use.

Tobacco exposure is strongly associated with lung cancer, and many lung cancer deaths could be avoided by preventing tobacco use and helping users quit. While the long-term relationship between vaping and lung cancer is still being studied, e-cigarettes should not be presented as risk-free. Many vaping products contain substances that are not intended for repeated inhalation into the lungs.

The concern is not only whether vaping causes the same diseases as smoking. The concern is also that vaping may sustain nicotine dependence, encourage dual use, expose the lungs to harmful chemicals, and increase the likelihood that some users will begin smoking traditional cigarettes.

Note: Respiratory therapists should avoid language that makes vaping sound harmless. A better approach is to explain that the long-term effects are still being studied, but vaping is known to involve inhaled chemicals and addictive substances that may affect lung health.

Nicotine Addiction and E-Cigarettes

Nicotine addiction is one of the major concerns associated with vaping. Many e-cigarette products contain high levels of nicotine, and some pod-based systems can deliver large amounts of nicotine efficiently. A small liquid pod may contain a nicotine dose comparable to a pack of cigarettes.

Nicotine affects the brain’s reward pathways, which can lead to dependence. This is especially concerning for adolescents and young adults because the developing brain is more vulnerable to nicotine’s effects. Early nicotine exposure can make quitting more difficult and may increase the likelihood of using other tobacco products.

Some patients believe vaping is a minor habit because it does not involve smoke or ash. However, nicotine dependence can still be strong. A person who vapes throughout the day may receive frequent nicotine doses, reinforcing addiction.

Respiratory therapists should assess nicotine dependence by asking how soon after waking the patient vapes, how often they use the device, whether they feel cravings, whether they have tried to quit, and whether they experience withdrawal symptoms. These details help guide education and cessation planning.

Youth Vaping and Public Health

Youth vaping is a major public health concern. E-cigarettes have been marketed in ways that may appeal to adolescents and young adults, including sleek device designs, sweet flavors, social media promotion, and easy concealment. Some devices look like common electronic items, making them difficult for parents and teachers to detect.

Adolescence is a critical time for prevention. People who do not start smoking during their teenage years are less likely to become smokers later in life. For this reason, nicotine exposure in teens is especially concerning.

E-cigarette use among young people can create several risks. It may lead to nicotine addiction, normalize inhaled substance use, increase experimentation with multiple tobacco products, and raise the likelihood of later cigarette smoking. Some studies have shown that e-cigarette users are more likely to progress to daily cigarette smoking compared with those who never use e-cigarettes.

Respiratory therapists may encounter young patients who vape but do not consider themselves tobacco users. This makes education important. Patients and families should understand that e-cigarettes can contain large nicotine doses and harmful chemicals, even when the product is flavored or marketed as modern, clean, or smoke-free.

Flavoring Chemicals and Lung Exposure

Many vaping liquids contain flavoring chemicals. These flavors may include fruit, candy, mint, dessert, or beverage-like flavors. While some flavoring chemicals may be safe to eat, that does not mean they are safe to inhale.

The lungs are designed for gas exchange, not repeated exposure to heated chemical aerosols. When flavoring agents are heated and inhaled, they may produce substances that irritate or injure the respiratory tract. Some chemicals associated with flavoring have been linked to serious lung disease.

One commonly discussed chemical is diacetyl, which has been associated with bronchiolitis obliterans, sometimes called popcorn lung. This condition involves inflammation and scarring of the small airways, which can lead to fixed airflow obstruction.

Not every vaping product contains the same chemicals, and not every user will develop lung disease. However, the presence of flavoring agents adds uncertainty and risk. Respiratory therapists should explain that flavor does not equal safety. A sweet or pleasant taste does not mean the substance is safe for inhalation.

Harmful Substances Found in E-Cigarettes

E-cigarette aerosols may contain several substances that are harmful to the lungs. These can include nicotine, heavy metals, volatile organic compounds, carcinogens, vegetable glycerin, propylene glycol, and flavoring chemicals.

Heavy metals such as nickel, tin, and lead may come from device components. Volatile organic compounds may be generated during heating. Propylene glycol and vegetable glycerin are common carrier substances in vaping liquids, but repeated inhalation of heated aerosols containing these substances raises respiratory concerns.

The risk depends on multiple factors, including the device, liquid, temperature, frequency of use, depth of inhalation, and substances added to the product. Some users modify devices or use homemade liquids, which can increase uncertainty.

Note: From a clinical standpoint, the exact product details matter. A patient who uses nicotine pods may have different exposure than someone who uses THC cartridges or homemade oils. This is why clinicians should ask specific questions instead of assuming all vaping is the same.

EVALI

E-cigarette or vaping product use-associated lung injury, known as EVALI, is an acute or subacute lung illness associated with vaping. It was first identified as a major outbreak in 2019. EVALI has also been called vaping-associated pulmonary injury or vaping-associated lung injury.

EVALI can be serious and sometimes fatal. Many patients require hospitalization, and more than half may require intensive care. Some patients develop severe respiratory failure and need mechanical ventilation.

EVALI is not one single disease pattern. It is an umbrella term used for lung injury associated with e-cigarette or vaping product use. Reported patterns include acute lung injury, acute respiratory distress syndrome, hypersensitivity pneumonitis, organizing pneumonia, lipoid pneumonia, diffuse alveolar hemorrhage, acute eosinophilic pneumonia, and respiratory bronchiolitis-associated pneumonitis.

Note: The exact cause of EVALI can vary and may not always be identified. Some cases have been associated with THC-containing products, vitamin E acetate, flavorants, oils, and other additives. However, no single device or liquid explains every case.

Symptoms of EVALI

Patients with EVALI may present with respiratory, gastrointestinal, and general symptoms. Common respiratory symptoms include shortness of breath, cough, chest pain, and worsening breathing difficulty. Some patients have fever, chills, fatigue, headache, dizziness, or rapid heart rate.

Gastrointestinal symptoms are also common and may include nausea, vomiting, diarrhea, and abdominal discomfort. This can make the presentation confusing because the illness may not initially appear to be purely respiratory.

Symptoms often worsen over days to weeks before the patient seeks medical care. The clinical picture may resemble pneumonia, influenza, COVID-19, or other acute respiratory infections. Because of this overlap, clinicians must rule out other possible causes.

Note: A vaping history is especially important in young patients with unexplained respiratory distress, bilateral pulmonary infiltrates, and systemic symptoms. Respiratory therapists should report recent vaping history to the healthcare team and include it in documentation.

Diagnosis of EVALI

There is no single diagnostic test for EVALI. Diagnosis is usually based on a combination of recent vaping history, symptoms, imaging findings, exclusion of other causes, and clinical judgment.

Common criteria include the presence of pulmonary infiltrates on chest x-ray or computed tomography within 90 days of e-cigarette or vaping product use, with no alternative cause identified after appropriate evaluation. Infections such as pneumonia, influenza, and COVID-19 must be considered and ruled out when appropriate.

Laboratory findings may be nonspecific. Some patients have elevated white blood cell counts or inflammatory markers. Imaging may show infiltrates in both lungs. CT scans can provide more detail when chest x-ray findings are unclear or when the patient is severely ill.

Bronchoscopy with bronchoalveolar lavage may be considered in selected patients to help evaluate for infection or other causes. Findings may include neutrophilia or lipid-laden macrophages, although these findings are not specific enough to diagnose EVALI by themselves.

Treatment of EVALI

Treatment for EVALI depends on severity. Mild cases may require close monitoring, vaping cessation, and follow-up. More severe cases may require hospitalization, oxygen therapy, antibiotics or antivirals while infection is being evaluated, corticosteroids to reduce lung inflammation, and ventilatory support.

Supportive oxygenation is often a key part of treatment. Patients with hypoxemia may need supplemental oxygen, high-flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation if respiratory failure develops.

Corticosteroids may improve symptoms in some cases, but treatment decisions depend on the patient’s condition and the clinician’s judgment. Since EVALI can resemble infection, clinicians often evaluate for infectious causes and may begin antimicrobial therapy until infection is excluded.

Follow-up is important after discharge. Patients should be counseled to stop vaping completely. Follow-up with a pulmonologist is often recommended, especially after hospitalization. Patients may need repeat imaging, pulmonary function testing, oxygen assessment, and monitoring for persistent symptoms.

Respiratory Therapist Role in EVALI

Respiratory therapists may be involved in the care of patients with suspected or confirmed EVALI in the emergency department, hospital, ICU, outpatient clinic, pulmonary function lab, and pulmonary rehabilitation setting.

At the bedside, the RT may help assess respiratory distress, monitor oxygen saturation, administer oxygen therapy, obtain arterial blood gases, assist with aerosolized treatments, support noninvasive ventilation, manage mechanical ventilation, and participate in patient education.

The RT should also help identify vaping history. Patients with acute lung disease should be asked specifically about e-cigarette use, THC products, nicotine pods, flavored liquids, refillable devices, shared cartridges, homemade products, dabbing, and frequency of use.

Note: Documentation should include the type of device, substance used, timing of last use, duration of use, symptoms, and whether the patient uses cigarettes or other tobacco products. This information can help the medical team evaluate risk and report suspected cases when appropriate.

Vaping and Smoking Cessation

Some people use e-cigarettes in an attempt to quit smoking. While this may seem appealing, major respiratory organizations do not recommend e-cigarettes as a standard smoking cessation method. The concern is that e-cigarettes have not been fully studied as a cessation strategy, may continue nicotine addiction, and may lead to dual use.

Evidence-based smoking cessation strategies should be recommended instead. These include behavioral counseling and FDA-approved medications. Options may include nicotine replacement therapy, varenicline, or bupropion, depending on the patient’s needs and provider recommendations.

Combining medication with counseling is generally more effective than either approach alone. Respiratory therapists can support cessation by asking about tobacco use, advising patients to quit, assessing readiness, connecting patients with resources, and reinforcing follow-up.

Note: Hospitalization can be an important opportunity for intervention. Patients may be more motivated to quit when illness has worsened their breathing or when they are in a smoke-free environment. RTs can use this moment to provide education and encourage evidence-based treatment.

Patient Education About Vaping

Patient education should be clear, accurate, and nonjudgmental. Many patients believe vaping is safe because it does not involve traditional cigarette smoke. Others believe it is only water vapor. Respiratory therapists should correct these misconceptions without shaming the patient.

A helpful message is that vaping may expose the lungs to nicotine, chemicals, metals, flavoring agents, and heated aerosols. The long-term effects are still being studied, but known concerns include addiction, airway irritation, lung injury, and increased risk of cigarette use among young people.

Education should be tailored to the patient. A teenager who vapes flavored nicotine pods may need a different conversation than an adult who smokes cigarettes and also vapes. A patient hospitalized with suspected EVALI needs direct counseling to stop vaping completely and avoid further exposure.

Note: Family education may also be important. Parents may not recognize vaping devices or may underestimate the nicotine content. Teaching families what devices look like and why they matter can support prevention.

Documentation and Screening

Respiratory therapists should document vaping in the medical record when relevant. This includes current use, former use, frequency, substances used, device type, and relationship to symptoms. Documentation helps other healthcare professionals understand the patient’s exposure history.

Screening questions should be specific. Instead of asking only, “Do you smoke?” clinicians can ask, “Do you smoke cigarettes, vape, use e-cigarettes, or use any nicotine or THC products?” This wording is more likely to identify patients who do not consider vaping to be smoking.

For patients with respiratory symptoms, follow-up questions should include when symptoms began, whether symptoms worsened after vaping, whether products were changed recently, and whether the patient used shared, modified, homemade, or THC-containing products.

Note: Accurate documentation can support diagnosis, education, public health reporting, and cessation planning.

Prevention and Health Promotion

Respiratory therapists have an important role in prevention and health promotion. This includes educating patients, families, schools, communities, and healthcare teams about the risks of tobacco use, vaping, and inhaled toxic substances.

Prevention should focus strongly on youth. Adolescents and young adults are vulnerable to nicotine addiction, and many vaping products are designed to be appealing and easy to hide. Teaching young people that vaping can deliver high nicotine doses and harmful chemicals may help reduce experimentation.

Community education may include asthma programs, COPD education, tobacco-use prevention, school presentations, public health campaigns, and smoking cessation programs. RTs can also help develop educational materials that explain the respiratory risks of vaping in simple language.

Note: Health promotion also includes advocating for smoke-free and vape-free environments. Patients with lung disease should be encouraged to avoid secondhand smoke, aerosol exposure, and other inhaled irritants.

Practical Takeaways for Respiratory Therapists

• Ask about vaping: A patient’s vaping history is part of respiratory assessment and should not be overlooked.
• Document vaping clearly: Include the type of device, substances used, frequency, duration, and symptoms.
• Educate patients that vaping is not harmless: E-cigarettes may contain nicotine, chemicals, metals, flavorings, and other inhaled substances that can affect the lungs.
• Avoid recommending vaping as a smoking cessation method: Evidence-based cessation methods, including counseling and FDA-approved medications, should be encouraged.
• Recognize possible EVALI: Patients with recent vaping history, respiratory symptoms, systemic symptoms, gastrointestinal symptoms, and pulmonary infiltrates may require evaluation for vaping-associated lung injury.
• Support prevention: Respiratory therapists are well-positioned to help reduce tobacco and vaping-related harm through patient education, cessation support, and community health promotion.

Vaping and E-Cigarette Practice Questions

1. What is vaping?
Vaping is the use of an electronic device to heat a liquid and create an aerosol that is inhaled into the lungs.

2. What are e-cigarettes?
E-cigarettes are electronic nicotine delivery devices that heat a liquid to produce an inhaled aerosol.

3. Why is vaping important in respiratory care?
Vaping is important because it exposes the lungs to inhaled chemicals, nicotine, flavoring agents, and other substances that may affect respiratory health.

4. Should respiratory therapists ask patients about vaping?
Yes. Vaping history should be included in the respiratory assessment along with smoking, occupational exposure, and environmental exposure.

5. Why should clinicians ask specifically about vaping instead of only asking about smoking?
Some patients who vape do not consider themselves smokers, so asking only about smoking may miss important exposure history.

6. What details should be included in a vaping history?
A vaping history may include the type of device, frequency of use, duration of use, nicotine concentration, substances vaped, and symptoms related to vaping.

7. How is vaping related to tobacco-use assessment?
Vaping is grouped with tobacco-related and nicotine-delivery products, so it should be assessed as part of the patient’s tobacco and inhaled exposure history.

8. Why should nicotine concentration be documented in patients who vape?
Nicotine concentration helps estimate addiction risk and the amount of nicotine exposure from the vaping product.

9. What respiratory symptoms may be associated with vaping?
Symptoms may include cough, shortness of breath, chest pain, wheezing, and worsening breathing difficulty.

10. What non-respiratory symptoms may occur with vaping-associated lung injury?
Non-respiratory symptoms may include fever, vomiting, diarrhea, headache, dizziness, nausea, and rapid heart rate.

11. What is EVALI?
EVALI stands for e-cigarette or vaping product use-associated lung injury.

12. When was EVALI first identified as a major clinical concern?
EVALI was first identified as a major clinical concern in 2019.

13. What are other names for EVALI?
EVALI may also be called vaping-associated pulmonary injury or vaping-associated lung injury.

14. Is EVALI always a mild condition?
No. EVALI can be severe, require ICU admission, lead to respiratory failure, and may be fatal.

15. What percentage of EVALI patients may require ICU admission?
More than 50% of patients with EVALI may require admission to an intensive care unit.

16. What imaging finding is commonly used in the diagnosis of EVALI?
Pulmonary infiltrates on chest x-ray or computed tomography are commonly used in the diagnostic evaluation.

17. Is there one single diagnostic test for EVALI?
No. EVALI is diagnosed through clinical evaluation, vaping history, imaging findings, and exclusion of other causes.

18. What conditions must be ruled out when evaluating possible EVALI?
Conditions such as pneumonia, influenza, COVID-19, and other causes of acute lung disease should be ruled out.

19. What time frame of vaping exposure is commonly used in EVALI case guidance?
Pulmonary infiltrates occurring within 90 days of e-cigarette or vaping product use are commonly used in case guidance.

20. What laboratory finding may be seen in patients with EVALI?
An elevated white blood cell count may be seen, although laboratory findings are nonspecific.

21. What treatment may be used for EVALI-related lung inflammation?
Corticosteroids may be used in some cases to help reduce lung inflammation.

22. Why might antibiotics or antivirals be used in suspected EVALI?
They may be used while clinicians evaluate and rule out infectious causes of the patient’s symptoms.

23. What supportive therapy may be needed for hypoxemic patients with EVALI?
Supportive oxygenation may be needed, including supplemental oxygen or ventilatory support in severe cases.

24. Why is follow-up important after hospitalization for EVALI?
Follow-up is important to monitor recovery, reassess lung function, evaluate persistent symptoms, and reinforce vaping cessation.

25. What should patients with EVALI be advised to do after discharge?
They should be advised to stop vaping and follow up with a pulmonologist or appropriate healthcare provider.

26. Why is nicotine addiction a major concern with vaping?
Nicotine addiction is a major concern because many vaping devices deliver high doses of nicotine that can lead to dependence.

27. How much nicotine may be found in a small e-cigarette liquid pod?
A small liquid pod may contain a nicotine dose equivalent to a pack of cigarettes.

28. Why are adolescents especially vulnerable to nicotine exposure?
Adolescents are especially vulnerable because nicotine can affect the developing brain and increase the risk of long-term addiction.

29. How can e-cigarette use affect future cigarette smoking risk?
E-cigarette use may increase the risk of progressing to daily cigarette smoking, especially among young users.

30. According to the information provided, how much more likely are e-cigarette users to progress to daily cigarette smoking?
E-cigarette users are three times more likely to progress to daily cigarette smoking compared with those who never use e-cigarettes.

31. Why is vaping considered a youth public health concern?
Vaping is a youth public health concern because it can introduce adolescents and young adults to nicotine addiction and other tobacco products.

32. What is the safest recommendation for patients after suspected vaping-related lung injury?
The safest recommendation is to stop vaping completely and avoid further exposure to e-cigarette or vaping products.

33. How can vaping contribute to airway irritation?
Vaping can expose the airways to heated chemicals, flavoring agents, and aerosols that may irritate lung tissue.

34. Why is trying tobacco before age 18 concerning?
Trying tobacco before age 18 is concerning because early nicotine exposure is associated with progression to cigarette smoking and long-term dependence.

35. What does dual use mean?
Dual use means a person uses more than one tobacco or nicotine product, such as cigarettes and e-cigarettes.

36. Why is dual use clinically important?
Dual use is important because the patient may continue cigarette smoke exposure while also maintaining nicotine addiction through vaping.

37. Why is it important to ask about vaping frequency?
Frequency helps estimate the amount of exposure and the possible relationship between vaping and respiratory symptoms.

38. Why should respiratory therapists ask about all nicotine products?
Respiratory therapists should ask about all nicotine products because patients may use cigarettes, e-cigarettes, smokeless tobacco, hookah, or other inhaled substances.

39. What is chemical pneumonitis?
Chemical pneumonitis is lung inflammation caused by inhaling irritating or toxic chemical substances.

40. Does uncertainty about long-term effects mean vaping should be considered safe?
No. Uncertainty does not mean vaping is safe, especially because known concerns include nicotine addiction, chemical exposure, and lung injury.

41. Why are flavored e-cigarettes concerning?
Flavored e-cigarettes are concerning because flavoring chemicals may be harmful when heated and inhaled into the lungs.

42. What is diacetyl associated with?
Diacetyl is associated with serious lung disease, including bronchiolitis obliterans.

43. What is bronchiolitis obliterans sometimes called?
Bronchiolitis obliterans is sometimes called popcorn lung.

44. Why does a pleasant flavor not make vaping safe?
A pleasant flavor does not make vaping safe because chemicals that are safe to taste or eat may not be safe to inhale after heating.

45. What harmful metals may be found in vaping aerosols?
Harmful metals may include nickel, tin, and lead.

46. What carrier substances are commonly found in e-cigarette liquids?
Vegetable glycerin and propylene glycol are common carrier substances found in e-cigarette liquids.

47. What other harmful substances may be present in e-cigarette aerosols?
E-cigarette aerosols may contain carcinogens, volatile organic compounds, heavy metals, flavoring chemicals, and nicotine.

48. Why can device design make youth vaping harder to detect?
Some vaping devices resemble pens, USB flash drives, or other everyday objects, making them easy to hide.

49. What does the AARC position statement say about e-cigarettes?
The AARC opposes the use of e-cigarettes, vapes, or devices used to aerosolize nontherapeutic liquids for inhalation.

50. Does the AARC recommend e-cigarettes as a smoking cessation method?
No. The AARC does not recommend e-cigarettes as a smoking cessation method.

51. What smoking cessation strategies are recommended instead of e-cigarettes?
Evidence-based smoking cessation strategies include FDA-approved medications, behavioral counseling, and follow-up support.

52. Why is counseling important for patients trying to quit nicotine?
Counseling helps patients understand triggers, build coping strategies, stay motivated, and reduce the chance of relapse.

53. What combination works best for smoking cessation?
A combination of medication and behavioral counseling works best for smoking cessation.

54. What role can respiratory therapists play in smoking cessation?
Respiratory therapists can assess tobacco use, educate patients, provide cessation counseling, and connect patients with treatment resources.

55. Why may hospitalization be a good time to discuss nicotine cessation?
Hospitalized patients may be more motivated to quit because their illness may be related to tobacco use and hospitals are smoke-free environments.

56. What should respiratory therapists avoid telling patients about vaping?
They should avoid telling patients that vaping is harmless or a proven safe replacement for smoking.

57. Why should RTs use a nonjudgmental approach when asking about vaping?
A nonjudgmental approach helps patients feel comfortable giving honest information about nicotine, THC, or other vaping product use.

58. What substances may patients vape besides nicotine?
Patients may vape THC, CBD, flavoring chemicals, homemade liquids, or other inhaled substances.

59. What is THC?
THC is tetrahydrocannabinol, the psychoactive compound found in marijuana.

60. What is CBD?
CBD is cannabidiol, a compound found in cannabis products that may be included in some vaping liquids.

61. Why are THC-containing vaping products clinically important?
THC-containing vaping products have been associated with many cases of EVALI and should be specifically assessed.

62. What does “dabbing” refer to in vaping history?
Dabbing refers to inhaling concentrated drugs or substances that are heated before vaping.

63. Why should clinicians ask whether cartridges or pods were shared?
Shared cartridges or pods may increase exposure risk and help clinicians understand the patient’s vaping behavior.

64. Why should clinicians ask whether old cartridges were reused?
Reused cartridges may have been refilled with homemade or commercial products, which can increase exposure to unknown substances.

65. What device details should be reported in suspected EVALI?
Clinicians should document the type of device used, such as bottles, cartridges, pods, or refillable systems.

66. What liquid details should be reported in suspected EVALI?
Clinicians should document whether the liquid contained nicotine, THC, CBD, flavorings, or other substances.

67. What vaping behavior details may be clinically useful?
Useful details include frequency of puffs, cloud volume, stealth vaping, zero vaping, and use of a Valsalva maneuver after inhalation.

68. Why is cloud volume relevant in vaping history?
Cloud volume may help estimate the amount of aerosol exposure and intensity of vaping behavior.

69. What is stealth vaping?
Stealth vaping refers to vaping in a way that minimizes visible aerosol so the behavior is harder to detect.

70. Why might patients with EVALI require mechanical ventilation?
They may develop severe respiratory failure that prevents adequate oxygenation or ventilation without support.

71. What does CT imaging often show in EVALI?
CT imaging may show infiltrates in both lungs.

72. What bronchoscopy finding may be seen in some EVALI cases?
Bronchoscopy with bronchoalveolar lavage may show neutrophilia and lipid-laden macrophages.

73. Are lipid-laden macrophages specific for EVALI?
No. Lipid-laden macrophages may be present but are not specific enough to diagnose EVALI alone.

74. What staining methods may be used to identify lipid-laden macrophages?
Oil Red O staining or Sudan staining may be used.

75. Why should suspected EVALI cases be reported?
Reporting helps public health agencies track cases, investigate causes, and identify harmful products or exposure patterns.

76. What is the main respiratory care takeaway about vaping?
The main takeaway is that vaping should be assessed, documented, and addressed as a clinically important inhaled exposure.

77. Why should vaping be included in bedside assessment?
Vaping should be included because it may affect pulmonary health and contribute to respiratory symptoms or disease risk.

78. Why should RTs ask about recent changes in vaping products?
Recent changes in devices, liquids, cartridges, or substances may help identify a possible trigger for new respiratory symptoms.

79. Why can EVALI be difficult to recognize at first?
EVALI can be difficult to recognize because its symptoms can resemble pneumonia, influenza, COVID-19, or other acute respiratory illnesses.

80. Why is vaping especially important to assess in young patients with unexplained dyspnea?
Young patients may vape even if they do not smoke cigarettes, and recent vaping can be linked to acute lung injury.

81. Why is vaping included with other inhaled exposures?
Vaping is included because it introduces substances directly into the respiratory tract, similar to other inhaled risks.

82. What patient statement may require clarification during assessment?
A patient who says they do not smoke may still vape, so the clinician should ask directly about e-cigarette use.

83. What is one reason vaping may be mistakenly viewed as safe?
Vaping may be viewed as safe because it does not produce traditional cigarette smoke.

84. Why is the term “vapor” potentially misleading?
The term “vapor” may be misleading because e-cigarettes create an aerosol that can contain nicotine, metals, chemicals, and other harmful substances.

85. What does the AARC tobacco-use-control statement support?
It supports eliminating tobacco use and exposure to inhaled toxic substances, including electronic cigarettes and vaping devices.

86. What types of inhaled substances are included in the AARC tobacco-use-control concern?
The concern includes tobacco, marijuana, electronic cigarettes, water-pipe smoking, vaping devices, and other inhaled toxic substances.

87. What should medical facilities do for patients who use tobacco or inhaled substances?
Medical facilities should identify these patients and provide interventions, pharmacotherapy, counseling, and follow-up when appropriate.

88. What type of respiratory therapist is strongly encouraged for tobacco-use treatment?
Respiratory therapists trained as tobacco treatment specialists are strongly encouraged.

89. Why is vaping relevant to community health promotion?
Vaping is relevant because it affects youth prevention, nicotine addiction, respiratory health education, and public awareness.

90. What educational materials may include e-cigarette information?
Educational kits for tobacco use, asthma, COPD, and e-cigarette use may include information about vaping risks.

91. Why should RTs educate families about vaping devices?
Families may not recognize vaping devices because some look like pens, USB drives, or everyday electronic items.

92. What is one danger of liquid nicotine solutions in children?
Liquid nicotine solutions can cause toxic exposure, and poison control centers have reported increasing calls related to these exposures.

93. Why is nicotine delivery to the brain concerning in newer devices?
Newer devices can deliver large amounts of nicotine to the brain, increasing addiction risk and potential harm to developing brains.

94. Why should vaping history include the duration of use?
Duration helps clinicians estimate the length of exposure and determine whether vaping may be related to current respiratory symptoms.

95. What should RTs recommend instead of vaping for quitting smoking?
RTs should support FDA-approved medications, behavioral counseling, and evidence-based cessation programs.

96. Why is follow-up important in tobacco cessation?
Follow-up helps monitor progress, reinforce quitting, manage relapse risk, and connect patients with continued support.

97. What is one major concern about marketing e-cigarettes to young people?
Marketing may encourage nicotine addiction in children, adolescents, and young adults.

98. Why are developing countries mentioned in relation to tobacco marketing?
They are mentioned because the tobacco industry has targeted developing countries as part of expanding tobacco and nicotine product use.

99. What is the relationship between vaping and patient education?
Vaping should be addressed during patient education because patients may misunderstand its risks and addiction potential.

100. What is the overall message about vaping in respiratory care?
The overall message is that vaping is not harmless and should be included in respiratory assessment, education, prevention, and cessation support.

Final Thoughts

Vaping and e-cigarettes are important respiratory care topics because they involve direct inhalation of nicotine, chemicals, flavoring agents, and other substances into the lungs. Although vaping is often promoted or perceived as safer than smoking, it should not be considered harmless.

Respiratory therapists should ask about vaping during assessment, document exposure history, educate patients about potential risks, recognize signs of vaping-associated lung injury, and support evidence-based tobacco cessation.

The goal is not to shame patients but to provide clear guidance that protects lung health and reduces preventable respiratory disease.